| Abbvie (3) |  |
| Alkaloid (11) | |
| Allergan (6) | |
| Astrazeneca (7) | |
| Basi (302) | |
| Bayer (10) | |
| Eisai company (3) | |
| Emergent biosolutions (4) | |
| F hoffmann la roche ltd (24) | |
| Glaxosmithkline (15) | |
| Merck & co (4) | |
| Novartis (22) | |
| Pfizer (10) | |
| Regeneron pharmaceuticals (3) | |
| Sanofi (5) | |
#Eisai launches In-house anticancer agent in Japan Japan's leading pharmaceutical company Eisai Co. Ltd. has launched its in-house developed novel anticancer agent Lenvima Capsule 4 mg
Discovered at Eisai's Tsukuba Research Laboratories and developed in-house, Lenvima is administered an orally molecular targeted agent that selectively inhibits the activities of several different molecules including VEGFR,
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011